trending Market Intelligence /marketintelligence/en/news-insights/trending/GzDzHdG5zcJaQ0iuXcqY8g2 content
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

Merck KGaA, Pfizer get FDA breakthrough status for kidney cancer therapy

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help


Merck KGaA, Pfizer get FDA breakthrough status for kidney cancer therapy

The U.S. Food and Drug Administration has granted breakthrough therapy status to Merck KGaA and Pfizer Inc.'s Bavencio, or avelumab, in combination with Inlyta to treat advanced kidney cancer.

Merck and Pfizer formed a strategic alliance to co-develop and co-commercialize avelumab in November 2014.

The agency's decision is based on the preliminary evaluation of clinical data from JAVELIN Renal 100, a phase 1b study assessing the safety and efficacy of avelumab in combination with Inlyta for treatment-naïve patients with advanced renal cell carcinoma.

Bavencio is approved by the FDA for the treatment of adults and pediatric patients 12 years and older with metastatic Merkel cell carcinoma and patients with locally advanced or metastatic urothelial carcinoma who have disease progression during or after platinum-containing chemotherapy, or have disease progression within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy.